Cross talk between the
angiotensin-converting enzyme (ACE)/
angiotensin II (Ang II)/Ang II type 1 (AT1) receptor axis and the ACE2/Ang-(1-7)/Mas axis plays a role in the pathogenesis of cardiovascular remodeling. Furthermore, possible stimulation of the Ang II type 2 (AT2) receptor by Ang-(1-7) has been highlighted as a new pathway. Therefore, we examined the possibility of whether the ACE2/Ang-(1-7)/Mas axis and Ang-(1-7)/AT2 receptor axis are involved in the inhibitory effects of AT1 receptor blockers on
vascular remodeling. Wild-type, Mas-knockout, and AT2 receptor knockout mice were used in this study.
Vascular injury was induced by
polyethylene-cuff placement around the mouse femoral artery. Some mice were treated with
azilsartan, an AT1 receptor blocker, or Ang-(1-7). Neointimal formation 2 weeks after cuff placement was more marked in Mas-knockout mice compared with wild-type mice. Treatment with
azilsartan or Ang-(1-7) attenuated neointimal area, vascular smooth muscle cell proliferation, increases in the
mRNA levels of
monocyte chemoattractant protein-1,
tumor necrosis factor-α, and interleukin-1β, and
superoxide anion production in the injured artery; however, these inhibitory effects of
azilsartan and Ang-(1-7) were less marked in Mas-knockout mice. Administration of
azilsartan or Ang-(1-7) attenuated the decrease in ACE2
mRNA and increased AT2 receptor
mRNA but did not affect AT1 receptor
mRNA or the decrease in Mas
mRNA. The inhibitory effect of Ang-(1-7) on neointimal formation was less marked in AT2 receptor knockout mice compared with wild-type mice. These results suggest that blockade of the AT1 receptor by
azilsartan could enhance the activities of the ACE2/Ang-(1-7)/Mas axis and ACE2/Ang-(1-7)/AT2 receptor axis, thereby inhibiting neointimal formation.